PETS Financials

Income Statement
MetricQ2 2027Q1 2027Q4 2026Q3 2026Q2 2026
Revenue
35.8M
-12.8%
41.0M
-4.2%
42.8M
+5.3%
40.7M
-8.3%
44.4M
Cost of Revenue
26.0M
-12.5%
29.7M
+11.0%
26.7M
-14.3%
31.2M
-2.3%
31.9M
Gross Profit
9.8M
-13.5%
11.3M
-29.5%
16.1M
+69.9%
9.5M
-23.8%
12.4M
Operating Expenses
16.2M
-7.6%
17.6M
-19.3%
21.8M
+9.2%
19.9M
-4.2%
20.8M
R&D
0
0
0
0
0
SG&A
14.0M
-8.9%
15.4M
-10.4%
17.2M
-1.8%
17.5M
-5.4%
18.5M
Operating Income
-6419000
-3.0%
-6232000
-9.5%
-5692000
+45.6%
-10469000
-24.9%
-8380000
EBITDA
-4237000
-3.7%
-4084000
-258.6%
-1139000
+85.9%
-8070000
-32.3%
-6102000
Net Income
-6434000
-4.7%
-6145000
-51.3%
-4061000
+61.5%
-10553000
-23.9%
-8520000
EPS (Basic)
$-0.31
-10.7%
$-0.28
-47.4%
$-0.19
+62.0%
$-0.50
-22.0%
$-0.41
EPS (Diluted)
$-0.31
-10.7%
$-0.28
-47.4%
$-0.19
+62.0%
$-0.50
-22.0%
$-0.41
Shares (Diluted)
21.1M
-2.8%
21.7M
+3.1%
21.0M
+0.1%
21.0M
+0.6%
20.9M
PetMed Express (PETS) — Financials